Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more competition for the HDAC antagonists dominating the field.

While HDAC inhibitors put epigenetic regulation on the map for cancer, the molecules have limitations that include hematologic toxicities...